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Blood  of patients  with  paroxysmal  nocturnal  hemoglobinuria  (PNH) 1 contains 
variable amounts of abnormal erythrocytes that are unusually sensitive to the hemo- 
lytic action of complement  (1,  2).  Lysis of these cells is mediated by the alternative 
pathway and  is enhanced  in serum of reduced  pH  (3-6).  The results of this  study 
suggest that the increased susceptibility of PNH erythrocytes to lysis by complement 
is due to a deficiency in membrane-associated, Factor H-like regulatory activity. 
Initiation of the alternative pathway is a spontaneous process (7, 8), resulting in the 
random  deposition  of C3b on cell surfaces  (9,  10).  C3b bound  to activators of the 
alternative pathway such as certain bacteria, fungi, viruses, and virus-infected cells, 
is relatively resistant  to inactivation  by the control  proteins Factors  H  and I. As a 
result,  the  number  of bound  C3b  molecules  rapidly  increases  due  to  the  positive 
feedback of the pathway (11). On nonactivating particles and host cells amplification 
of C3b deposition is largely prevented by the action of Factors H  and I. However, the 
present evidence suggests that at least on human erythrocytes this mechanism is not 
entirely sufficient to prevent cytolysis and that membrane constituents  are required 
for efficient control of complement activation. 
It is known that human erythrocytes possess at least two membrane proteins that 
regulate complement: the C3b receptor (12)  and the decay-accelerating glycoprotein 
(13).  These proteins have been isolated and found to have Factor H-like activities, 
suggesting a  role in  controlling  activation of complement  (12,  13).  These activities 
include  inhibition  of Factor B  binding to C3b, acceleration of the decay of the C3 
convertase, C3b,Bb, and enhancement of cleavage and inactivation of C3b by Factor 
I. It is the purpose of this paper to demonstrate that the abnormal erythrocytes in the 
blood of three PNH patients lack these functions and to propose that this deficiency 
is a manifestation of the molecular defect underlying PNH. 
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1 Abbreviations used in this paper: E, erythrocytes; EC3b, erythrocytes  bearing surface-bound C3b; EDTA, 
ethylenediaminetetraacetic acid; EGTA, ethylenebis (oxyethylenenitrilo)-tetraacetic  acid; FACS, fluores- 
cence-activated cell sorter; FITC, fluorescein isothiocyanate; GVB, VBS containing 0.1% gelatin; GVBE, 
GVB containing 10 mM EDTA; PNH, paroxysmal  nocturnal hemoglobinuria; VBS, 10 mM veronal, 150 
mM NaCl, pH 7.4. 
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Materials  and  Methods 
Purified Proteins and Reagents.  C3  (14),  nephritic factor (15),  cobra venom factor (16),  and 
Factors B  (17),  D  (18),  H  (19),  and  I  (19)  were  prepared  as described elsewhere.  C3  was 
fluoresceinated (FITC-C3) by incubating 9.1 mg C3 with 0.2 mg fluorescein isothiocyanate in 
2 ml of 50 mM NayCO3 buffer at pH 9 for 50 min at 220C. FITC-C3 was separated from free 
fluorescein by gel filtration on Sephadex G25. TPCK-trypsin was purchased from Worthington 
Biochemical Corp., Freehold, NJ. Buffers used were: VBS, 10 mM veronal, 150 mM NaC1, pH 
7.4; GVB, VBS containing 0.1%  gelatin; GVBE, GVB containing 10 mM EDTA. Iodination 
of C3 and Factor B was performed using Iodogen (Pierce Chemical Co., Rockford, IL) according 
to the manufacturer's directions. 
Preparation of C3b-Bearing Erythrocytes.  Blood was  drawn  into  EDTA  and  the  cells were 
washed  first  with  GVBE,  then  with  GVB.  Deposition  of C3b  from  the  fluid  phase  was 
performed using the cobra venom  factor-dependent C3 convertase instead of trypsin (20)  in 
order to prevent protease-induced changes in cell surface proteins. Erythrocytes (6 ×  10  a) were 
suspended in 364 #g of C3 in 200/~1 and incubated with 34/~g of cobra venom factor-dependent 
C3 convertase (2 i) for 30 rain at 37°C. The deposited C3b was amplified as previously described 
(20) using the cell-bound, nephritic factor-stabilized C3 convertase and C3 or FITC-C3. 
Fluorescence-activated Celt Sorter (FAGS) Analysis.  Erythrocytes bearing specifically deposited 
s  FITC-C3b were suspended in GVBE at 10/ml. FACS analysis was performed on 100,000 cells 
of each type (normal human erythrocytes, PNH erythrocytes, and sheep erythrocytes) using a 
Becton-Dickinson model FACS IV (B-D FACS Systems, Becton, Dickinson & Co., Sunnyvale, 
CA). 
Acidified Serum Assay.  This test (5) was modified to exclude classical pathway participation 
by including EGTA (ethylenebis (oxyethylenenitrilo)-tetraacetic  acid, J.T. Baker Chemical Co., 
Phillipsburg, N  J). Normal human serum was acidified to pH 6.4 using 1 N  HC1. The percent 
lysis was determined after incubating 107 erythrocytes with varying amounts of acidified serum 
in GVB containing 2.5 mM MgC12 and 2.5 mM EGTA for 30 min at 37°C. 
Decay Rate of C3 Convertase.  ~25I-Factor B  (0.75/zg at 2.3/~Ci//.tg), Factor D  (0.5 #g), and 5 
X  107 EC3b were incubated for 3 min at 22°C in 60 #1 GVB containing 5 mM MgCle. GVBE 
(440 #1) was added to stop further enzyme formation. Samples (50 #1) were removed, layered on 
20% sucrose, and centrifuged 60 s in a  Beckman Model  152  Microfuge to separate cells from 
unbound protein (20). 
Cleavage of Cell-bound C3b by Factor I.  In order to measure cleavage by Factor I in the absence 
of Factor H  a modification of a previously described method (22) was used. Erythrocytes (5 × 
10  s) bearing C3b deposited with the nephritic factor-stabilized C3 convertse as described above 
were first incubated with Factors B, D, and 5 mM MgC12 for 2 min at 37°C, then with leSI-C3 
in GVBE to deposit radiolabeled C3b. The cells were incubated with various concentrations of 
Factor I in GVBE (100/~1) for 10 min at 37°C. The cells were washed once and resuspended in 
1 ml  GVBE  containing  2 #g  trypsin. After 5  min  at  37°C  the  supernatant  was  removed, 
combined with the first wash, and the released radioactivity determined. Background was the 
release in the absence of Factor I, 100% was taken as the release that occurred when 80 #g/ml 
of Factor H  was present along with 78 #g/ml Factor I during the 10-min incubation. 
Determination of the Number of C3b Receptors on Human Erythrocytes.  The number of C3b receptors 
present on PNH erythrocytes and normal human erythrocytes and the affinity of the receptors 
for C3b was determined using radiolabeled dimeric C3b. The preparation of C3b dimers and 
the assay procedure have been pre~,iously described (23). 
Results 
Characterization  of the PNH E~ythrocyte Population by FACS Analysis.  EC3b  was  pre- 
pared  from  the  erythrocytes  of a  patient  (T.  J.)  with  PNH  and  from  a  normal 
individual using FITC-C3  and  the C3  convertase  of the  alternative pathway.  The 
resulting cells bearing FITC-C3b were washed  free of unbound  fluorescent  protein 
and  subjected  to  FACS  analysis.  The  results  indicated  that  the  normal  sample 
contained  essentially one  population of EC3b  with  a  low concentration  of C3b  on PANGBURN  ET AL.  1973 
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FIG.  1.  Fluorescence-activated cell sorter analysis of PNH (T. J.) and normal human erythrocytes 
bearing FITC-labeled C3b. The abscissa indicates the relative fluorescence intensity of the cells. 
The ordinate shows the number of cells found in each increment (channel) of fluorescence intensity. 
Erythrocytes  were  prepared  as  described  in  Materials and  Methods  utilizing fluid phase  C3 
convertase to deposit the initial C3b and the cell-bound nephritic factor-stabilized enzyme to deposit 
FITC-C3b. As a reference, the upper panel shows the distribution of normal human erythrocytes 
without FITC-C3b (dashed line). The results show that PNH erythrocytes (T. J.) exhibited two 
populations of cells (center  panel) and that the population that acquired the highest levels of FITC- 
C3b was lost (lower  panel)  when the cells were treated with acidified human serum before C3b 
deposition. 
their  surface  (Fig.  1).  The  PNH  samples  contained  two  populations  of cells, one 
exhibiting low C3b fluorescence like the normal erythrocytes and the other showing 
approximately eightfold  higher  fluorescence  intensity.  The  second  population  was 
composed of 43% of the cells and contained 83% of the cell-bound FITC-C3b. When 
the  PNH  erythrocytes  were  exposed  to  acidified  (pH  6.4)  normal  human  serum 
containing EGTA, 44% of the cells lysed (Fig. 2). The unlysed cells were washed and 
FITC-C3b was deposited on their surface as described above. FACS analysis revealed 
a  single population of EC3b  resembling normal EC3b  (Fig.  1).  The removal of the 
EC3b bearing high numbers of C3b molecules by alternative pathway mediated lysis 
identified these cells as the abnormal PNH  erythrocytes. 
Enhanced Stability of the C3 Convertase, C3b,  Bb on PNH E~ythrocytes Compared to Normal 
Human  Erythrocytes.  Decay-dissociation of C3b,Bb  bound  to  PNH  erythrocytes  or 
normal erythroeytes was measured by the release of radiolabeled Bb at 22°C  (Fig. 3). 
Whereas the half-life of the enzyme on normal erythrocytes was  2.2 min,  it was  7.6 
min for the C3 convertase bound to PNH  erythrocytes (T. J.).  Because the majority 
of C3b  molecules were bound  to the abnormal erythrocytes in the PNH  sample, as 
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FIG. 2.  Lysis of PNH erythrocytes via the alternative pathway in acidified normal human serum. 
Cells were incubated for 30 rain at 37°C with the indicated amounts of serum adjusted to pH 6.4. 
The reaction mixtures contained 2.5 mM MgCI2 and 2.5 mM EGTA to prevent classical pathway 
activation. 
erythrocytes and not on the normal erythrocyte population present in the sample. It 
was also noted that formation of C3b,Bb on normal erythrocytes was only one-third 
as efficient as on PNH erythrocytes. For these reasons the contribution of the enzyme 
on the normal erythrocyte population  to the observed decay rate of the enzyme on 
PNH erythrocytes was small.  For comparison, the half-life of the C3 convertase on 
sheep erythrocytes, which was similar to that of the unregulated enzyme in the fluid 
phase at 22°C, is also shown. 
Reduced Susceptibility  of C3b on PNH Erythrocytes to Inactivation by Factor 1.  Cleavage of 
C3b by Factor I in the absence of Factor H  was determined on PNH, normal human, 
sheep, and rabbit erythrocytes (Fig. 4). The cells of three patients with PNH (J. H., 
K. W., and T. J.)  were examined by this assay and the results were similar in each 
ease. To cleave 50% of the C3b on PNH erythrocytes,  100  times more Factor I was 
required than for the same extent of cleavage of C3b on normal human erythrocytes. 
C3b  on  sheep  erythrocytes resembled C3b  on  PNH  erythrocytes, whereas  C3b  on 
rabbit  erythrocytes was completely resistant  to Factor I  as is  fluid phase C3b  (19). 
C3b bound to other strong activators of the alternative pathway such as zymosan and 
inulin was similarly resistant. Treatment of erythrocytes with  1 mg/ml trypsin for 30 
min at 37°C or with neuraminidase (20)  before C3b deposition did not significantly 
alter the results of this assay. Trypsin treatment of normal human erythrocytes did, 
however, inactivate the immune adherence function. 
Reduced Number of C3b Receptors on PNH Erythrocytes.  The number of C3b receptors 
on estimated using radiolabeled  C3b-dimers as the  ligand  (23).  Compared to  four 
samples of normal  human  erythrocytes,  the  binding  curves  for  PNH  erythrocytes PANGBURN  ET  AL.  1975 
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Fro.  3.  Comparison of the decay rates at  22°C of the C3 convertase, C3b,Bb,  bound to PNH, 
normal human or sheep erythrocytes. The half-life of C3b,Bb on PNH erythrocytes (7.6 min) was 
3.5 times longer than the half-life on normal human erythrocytes (2.2 min). The half-life on sheep 
erythrocytes  was  10.9  min.  For  reasons stated  in  the  text  the  observed  decay  rate  with  PNH 
erythrocytes was  primarily  that  of the  population  of cells  which  were  abnormally sensitive to 
complement. 
showed similar affinities but lower saturation levels. Receptor saturation averaged 64 
+  2% of normal for patient J. H. and 58 -  6% of normal for patient T. J. If one of the 
two cell populations of patient T. J.  bears a  normal number of receptors then the 
results suggest that 42% of the cells lack C3b receptors. This percentage corresponds 
to the values obtained for the abnormal cells by FACS analysis (Fig.  1)  and by the 
acidified serum lysis test (Fig. 2). 
Discussion 
The C3b receptor of normal human erythrocytes has been identified as a  205,000- 
dalton glycoprotein that  is functionally characterized by its ability to bind C3b, to 
block binding of Factor B to C3b, to dissociate the C3b,Bb enzyme and to modulate 
C3b and C3bi for cleavage by Factor I  (12, 24-31). A second regulatory glycoprotein 
has been isolated from human erythrocytes (13). This protein, which has a molecular 
weight  of  70,000  daltons,  has  greater  decay-accelerating  activity  toward  the  C3 
convertase of the classical pathway than toward the properdin-stabilized C3 conver- 
tase of the alternative pathway. In most of these functions the two membrane proteins 
resemble the regulatory protein Factor H, which is a  150,000-dalton serum glycopro- 
tein. The results of the present study suggest that the abnormal PNH erythrocytes are 
deficient in membrane-associated Factor H-like activity. These Factor H-like functions 
have  been  implicated  as  a  protective  mechanism  of human  erythrocytes against 
hemolysis by complement (12, 13, 28). This deficiency in PNH erythrocyte  membranes 
may represent the molecular basis of the disease. 1976  PAROXYSMAL  NOCTURNAL HEMOGLOBINURIA 
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FIO. 4.  Influence of erythrocyte surface on inactivation of hound C3h by Factor I in the absence 
of Factor H, Radiolabeled C3b hound to normal human erythrocytes was converted to C3bi 100- 
fold  more  efficiently than  C3b  bound  to  PNH  or sheep erythrocytes. C3b  bound  to  rabbit 
erythrocytes, an efficient activator of the human alternative pathway, or fluid phase C3b (19) were 
not susceptible to Factor I without Factor H. 
The abnormal  PNH  cells  in  the  total  erythrocyte population  from patients  with 
PNH were identified  by FACS analysis.  The abnormality allowed  greatly increased 
deposition of C3b by the cell-bound C3 convertase (32). The C3b-rich cell population 
was shown to be highly susceptible to lysis by acidified serum, which is an established 
characteristic of PNH cells  (1, 2). 
Normal  human  erythrocytes  are  completely resistant  to lysis  by acidified  serum. 
Sheep erythrocytes, like normal human erythrocytes, are considered nonactivators of 
the alternative pathway. However, sheep erythrocytes resemble PNH cells with respect 
to lysis in acidified serum.  In light  of the present  findings it  is probably significant 
that sheep erythrocytes lack (33) or possess only weak (Fig. 4) Factor H-like regulatory 
activity on their surface. The mechanism of hemolysis in acidified serum  is unclear, 
although it has been shown that the association of C3b and Factor B is enhanced at 
pH  6.5,  as  compared  with  physiological  pH,  and  that  mere  incubation  of human 
serum at pH 6.5 results in enhanced spontaneous activation of the alternative pathway 
(34). 
That PNH erythrocytes bind much more C3b than normal cells during complement 
activation  has  been  demonstrated  (6).  This  fact  has  been  attributed  to  a  greater 
apparent enzyme activity of the C3 convertase bound to PNH erythrocytes than that 
bound to normal human erythrocytes (32). The present study revealed two additional 
properties of the abnormal PNH cells that result in enhanced C3b deposition. It was 
found that C3b,Bb is more stable on PNH erythrocytes than on normal erythrocytes 
and that C3b is more resistant  to inactivation by Factor I. The enhanced stability of 
the C3 convertase on PNH erythrocytes was not detected in a previous study because PANGBURN  ET  AL.  1977 
that  study employed the  nephritic  factor-stabilized enzyme  (32).  The resistance of 
C3b on PNH erythrocytes to inactivation affords enhanced C3 convertase formation 
and the increased stability of the enzyme affords increased C3b deposition. 
The  C3b  receptor  on  normal  human  erythrocytes enters  into  a  receptor-ligand 
interaction with C3b covalently linked to other particles or ceils, thereby mediating 
immune  adherence.  It  has  been  shown  that  the  isolated  C3b  receptor  of human 
erythrocytes  accelerates  decay-dissociation  of the  C3  convertases  C3b,Bb  (12)  and 
C4b,2a  (24,  35)  and  that  it  renders  C3b  susceptible  to  inactivation  by  Factor  I. 
Inactivated C3b has lost the ability to bind Factor B, C5, or C5b-6. Since the results 
indicated the absence of the Factor H-like activities on PNH erythrocytes, the question 
arose  as  to  the  presence of C3b  receptor  function  on  the  abnormal  cells.  In  both 
patients examined the total number of erythrocyte receptors was depressed. However, 
due to the large variation among normal individuals of the number of C3b receptors 
on erythrocytes (13, 23,  36)  the lower values observed are inconclusive. The finding 
that  trypsin  inactivates  receptor  function,  but  not  the  C3b,Bb  decay-accelerating 
activity on normal human erythrocytes, also suggests caution in assigning the defect 
to the C3b  receptor.  It will  be necessary to isolate the abnormal PNH erythrocyte 
population in order to evaluate the presence or absence of C3b receptor function, and 
if absent to determine whether the receptor protein is lacking or is present in inactive 
form. 
On the basis of the data presented and the known regulatory functions associated 
with the membrane of normal human erythrocytes, a defect in one or more regulatory 
factors would be expected to have the following consequences. C3b randomly depos- 
ited on these cells from the fluid phase, would be less susceptible to inactivation by 
Factor I, would be more likely to form a C3 convertase, and the C3 convertase would 
be more stable and  more likely to  form a  C5  convertase.  Because of the  increased 
stability  of the  C3b  subunit  of the  C5  convertase,  C5,  C5b,  and  C5b-6  would  be 
handled  more effectively in the  initiation  of membrane attack  (37).  The net  result 
would be that initially deposited C3b molecules would be more likely to succeed in 
producing a lytic event on PNH cells than would C3b on normal human erythrocytes. 
Summary 
Erythrocytes  from  patients  with  paroxysmal  nocturnal  hemoglobinuria  (PNH) 
contained  a  subpopulation  that  lacked membrane-associated Factor H-like activity 
present on normal human erythrocytes. Initial deposition of C3b on the erythrocytes 
was  effected using  a  fluid  phase  C3  convertase.  The  cells  were  then  treated  with 
fluorescein-labeled  C3  and  the  cell-bound  C3  convertase.  Analysis  utilizing  the 
fluorescence-activated cell sorter revealed two distinct cell populations, one of which 
was highly fluorescent, indicating a large number of C3b molecules per cell. Only this 
population  (43%)  was  susceptible  to  lysis  (44%)  when  exposed  to  acidified  serum 
before  C3b  deposition.  The  less  fluorescent  population  resembled  normal  human 
erythrocytes and was not affected by prior treatment with acidified serum. 
Since C3b deposition occurred almost exclusively on the complement-sensitive cells 
in the PNH erythrocyte population, these cells could be examined for the Factor H- 
like regulatory activities without prior isolation. These functions include enhancement 
of inactivation of erythrocyte-bound C3b by Factor I and acceleration of the decay of 
erythrocyte-bound C3 convertase, C3b,Bb.  It was found that C3b on PNH erythro- 1978  PAROXYSMAL  NOCTURNAL HEMOGLOBINURIA 
cytes was  100-fold less susceptible  to inactivation  by Factor I  than  C3b  on normal 
human  erythrocytes.  The  half-life  at  22°C  of C3b,Bb  on  PNH  erythrocytes  was 
threefold  greater  than  on  normal  human  erythrocytes  and  similar  to  that  of the 
enzyme bound to particles that do not possess Factor H-like activity. These observa- 
tions  suggest  that  the  abnormal  susceptibility  of  PNH  erythrocytes  to  lysis  by 
complement  is  due  to  a  functional  deficiency in  one  or more  of the  Factor  H-like 
proteins present on normal human erythrocytes. 
Note added in proof'. The IgG fraction of antiserum to purified DAF inhibited the decay- 
accelerating activity on normal human erythrocytes. It did not affect cleavage of C3b 
by Factor I. Antiserum to purified CR1 did not affect the decay-accelerating activity 
on normal human erythrocytes, while completely inhibiting cleavage of C3b by Factor 
I. These results suggest that the two activities examined  in this paper are properties 
of two  distinct  molecules  on  normal  human  erythrocytes that  may be  deficient  on 
PNH erythrocytes. 
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